Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13868443 | 0.87 | NQO2 (0.52) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL31508264 | 0.82 | CYP2A6 (0.83) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL12068478 | 0.82 | CYP2A6 (0.83) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL12108682 | 0.82 | CYP2A6 (0.83) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL12956908 | 0.82 | CYP2A6 (0.83) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL30579341 | 0.82 | SMN1; SMN2 (0.57) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL4631802 | 0.82 | SMN1; SMN2 (0.57) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL1690651 | 0.81 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL2751114 | 0.81 | CYP2A6 (0.65) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 | |
| SCHEMBL19786693 | 0.81 | CYP19A1 (0.65) | CYP2A6ALDH1A1CYP3A4CYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289818-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| WO-2024193689-A1 | PYRIDINOPYRROLE DERIVATIVE AND USE THEREOF IN DRUGS | 广东东阳光药业股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| CN-118684665-A | Pyridopyrrole derivatives and their use in medicine | 广东东阳光药业股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-115151534-B | Inhibitors of interleukin-1 receptor associated kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof and methods of use thereof | 南京药石科技股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230067929-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230067929-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| CN-115151534-A | Inhibitors of interleukin-1 receptor-related kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof, and methods thereof | 南京药石科技股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-3898614-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | Tolremo Therapeutics AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021159993-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR ASSOCIATED KINASE (IRAK) /FMS-LIKE RECEPTOR TYROSINE KINASE (FLT3), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2021-08-19 | — | — | WO | disclosed |
| WO-2020127200-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-2852584-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2013174780-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174780-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| US-7524860-B2 | Antibacterial agents | PFIZER INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524860-B2 | Antibacterial agents | PFIZER INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080021059-A1 | Antibacterial Agents | PFIZER INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021059-A1 | Antibacterial Agents | PFIZER INC. (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | PDXK, PRMT1, DMPK | CYP2A6 4210/4885ALDH1A1 1040/4885CYP3A4 3501/4885 |
| US-20250289818-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | SLC10A1, SLC6A6, SLC10A6 | CYP2A6 249/4885ALDH1A1 841/4885CYP3A4 461/4885 |
| US-20080021059-A1 | Antibacterial Agents | CLPP, QDPR, CLSPN | CYP2A6 1897/4885ALDH1A1 3118/4885CYP3A4 1074/4885 |
| US-20230067929-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | SLC10A1, SLC6A6, SLC10A6 | CYP2A6 202/4885ALDH1A1 932/4885CYP3A4 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.